News

Alkermes Scheduled to Discuss Q1 Financial Performance Soon

Alkermes Scheduled to Discuss Q1 Financial Performance Soon

Alkermes to Present First Quarter Results on May 1

Alkermes plc (Nasdaq: ALKS) is set to hold a significant conference call on May 1, where they will discuss their financial results for the first quarter of the year. This event is anticipated to provide crucial insights into the company's performance and future strategies.

Conference Call and Webcast Details

The conference call will start at 8:00 a.m. ET, which corresponds to 1:00 p.m. BST. Interested parties can participate in the call by dialing the U.S. number +1 877 407 2988 or the international number +1 201 389 0923. The call will also be streamed live via a webcast, details of which can be found on the Investors section of Alkermes' corporate website.

Access to Webcast Replay

For those unable to join the live call, Alkermes will provide a replay of the webcast about two hours after the conclusion of the event. This replay will be accessible through Alkermes' website, ensuring that stakeholders can stay informed about the company's developments.

Understanding Alkermes plc

Alkermes plc is a renowned global biopharmaceutical company dedicated to advancing innovative medicines in the neuroscience sector. The company's offerings include proprietary products aimed at treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes is actively involved in the development of clinical and preclinical candidates aimed at neurological disorders like narcolepsy and idiopathic hypersomnia.

Headquarters and Operations

Headquartered in Ireland, Alkermes maintains a robust research and development presence with facilities located in Massachusetts and a manufacturing center in Ohio. This diverse operational footprint supports the company’s commitment to producing effective therapies while advancing groundbreaking research in its field.

Contact Information

For further inquiries, contact Jamie Constantine from Investor Relations at +1 781 873 2402. Alkermes remains committed to transparency and communication with its investors and stakeholders.

Frequently Asked Questions

When will Alkermes report its first quarter financial results?

Alkermes is scheduled to report its first quarter financial results on May 1.

How can I access the conference call?

You can access the conference call by dialing +1 877 407 2988 for U.S. callers or +1 201 389 0923 for international callers.

Is there a way to listen to the replay of the call?

Yes, a replay of the webcast will be available two hours after the event on Alkermes' website.

What therapeutic areas does Alkermes focus on?

Alkermes focuses on developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, among others.

Where is Alkermes headquartered?

Alkermes is headquartered in Ireland, with additional facilities in Massachusetts and Ohio.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Western Microsurgical Expands Through Strategic Acquisitions

Updated Category News Views 50

Western Microsurgical's Bold Moves Western Microsurgical (WMS) is out here making waves, pulling off some serious strategic plays with the acquisitions of Q Surgical and Proficient Surgical. Now, this ain't some fly-by-night decision—this is about securing territory and leveling up their game in surgical microscopes and operating room supplies. With a footprint that'll...

Continue Reading
Fashion Sees Quality Trumping Price in Consumer Preferences

Updated Category News Views 6

Consumers Are Shifting Away from Price-First Mindset You could always count on shoppers looking for a bargain, right? Well, hold your horses, 'cause that train's rolling off the tracks. In today's fashion shuffle, good ol' quality and craftsmanship are giving low prices a run for their money. A study spearheaded by Boston Consulting Group (BCG) and Women's Wear Daily...

Continue Reading
Nektar Therapeutics Gears Up for Q3 Financial Reveal

Updated Category News Views 34

Anticipation Builds as Nektar Preps Financial Report Ah, the life of a biotech investor, riding high or gripping the rail as tides turn with every quarterly report. This time, we're turning our gaze to Nektar Therapeutics and their Q3 financial results slated for release on November 12th, just as the market dust starts settling for the day. Now, if you’re wired to...

Continue Reading
Innodata Faces Investigation After Major Stock Drop

Updated Category News Views 26

Rough Waters for Innodata, Stock Takes a Hit The market can be a brutal place when news hits hard, and that's precisely the situation Innodata Inc. (NASDAQ: INOD) found itself in on October 27, 2026. After a promising rally, the company's shares plummeted by over 20% when news broke of a significant workforce reduction overseas. Unpacking the Numbers Behind the Dive The...

Continue Reading
MillerKnoll's 3D Push: Legacy Meets Innovation

Updated Category News Views 42

Bringing the Classics to the Digital Frontier Here's what's lighting a fire under the world of high-end furniture: MillerKnoll's got its eye on the prize by jazzing up Knoll.com with shiny new 3D product configurators. It's like taking a century's worth of design stuffiness and spinning it into the future, ready to dazzle a whole new set of eyeballs. Why This Move Matters...

Continue Reading
Nakama's AniBiz Gains Power with New Investments

Updated Category News Views 43

Anime Titans Back AniBiz Think of the anime sector with a new sheriff in town, and its name is AniBiz.com. This platform, a brainchild of Nakama, Inc., just landed strategic investments from some heavyweight players in the anime world: TBS Group, Toei Animation, and TV TOKYO Holdings. The Significance of Strategic Support Ain’t no small potatoes here. We're talking the...

Continue Reading
Posterity Health Boosts Network to Six New Markets

Updated Category News Views 132

Expansion at Breakneck Speed Just like that, we've got Posterity Health making power moves across the country, staking claim in six major markets. Denver's very own fertility platform is on a roll, and this ain't just any rollout. We're talking partnerships like confetti in the air, dotting spots from the sunny Cali shores of Orange County to the bustling streets of...

Continue Reading
Henlius Reports Strong Outcomes in U.S. Serplulimab Study

Updated Category News Views 180

Henlius has got tongues wagging with some hefty news out of their recent ASTRIDE trial. They've chalked up some promising results in terms of survival for folks staring down Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Now, in the perennial footrace between science and disease, this is one of those rare moments where you feel like science might just pull ahead—for...

Continue Reading
Set Hach: A Leader Transforming Agrifood Systems

Updated Category News Views 89

From Humble Beginnings to Global Recognition When a name like Set Hach doesn't just echo within local circles but reaches the global stage, you know something transformative is brewing. Here we have a woman celebrated as one of the 100 Women Heroes in Agrifood Systems by the UN Food and Agriculture Organization (FAO). Recognition like this speaks volumes, especially...

Continue Reading
Peloton Broker: Streamlining Energy Land Deals

Updated Category News Views 41

Peloton's New Broker Tool: What Miners and Developers Should Know Here's one for the energy folk who are up to their ears in land titles and lease talk. Peloton just threw a wrench in the scattered land data mess with Peloton Broker. Think of it as the 'new kid on the block' in their Land Data Management solution, designed to untangle the madness that often clogs the...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future Growth of Warehouse Management Systems

Updated Category News Views 75

Market Growth and Dynamics Overview The Warehouse Management System (WMS) market is witnessing remarkable growth, fueled by the surge in e-commerce and technology advancements. According to recent reports, this sector was valued at USD 3.50 billion in 2023, with expectations to reach USD 13.53 billion by 2032. This rapid ascent represents a compound annual growth rate...

Continue Reading
Investors Have a Chance to Join the Block, Inc. Legal Action

Updated Category News Views 402

Block, Inc. Class Action Lawsuit Overview Investor awareness is crucial when it comes to participating in legal actions, especially in securities fraud cases. Recently, a significant opportunity has emerged for investors in Block, Inc. to lead a class action lawsuit. This legal action was initiated by The Schall Law Firm, a prominent national shareholder rights litigation...

Continue Reading
Praxis Precision Medicines' New Stock Option Grants Overview

Updated Category News Views 235

Exciting Developments at Praxis Precision Medicines Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a pioneering biopharmaceutical firm, has made headlines with its latest announcement regarding stock option grants. The company is on a mission to transform genetic insights into effective therapies for central nervous system (CNS) disorders, particularly those involving...

Continue Reading
Shelf Intelligence: The Retail Revolution Transforming Shopping

Updated Category News Views 247

Shelf Intelligence: A Game Changer in Retail Shelf intelligence is rapidly becoming a focal point for retailers aiming to enhance their operations and customer experience. As the retail landscape evolves, leaders are recognizing the need for technologies that not only improve inventory accuracy but also boost profitability and elevate customer satisfaction levels. This...

Continue Reading
BlueHalo's New Contract Enhances UAS Electronic Warfare Capabilities

Updated Category News Views 285

BlueHalo Secures Strategic Contract for Electronic Warfare Systems BlueHalo has recently been awarded a significant contract valued at $49.9 million by the Naval Information Warfare Center (NIWC) Pacific. This five-year agreement signifies a major step forward in enhancing Uncrewed Aerial Systems (UAS) through advanced Electronic Warfare (EW) capabilities. Commitment to...

Continue Reading